Commercialisation: qutbluebox

 bluebox innovation

qutbluebox pty ltd ('bluebox') is the technology transfer and commercialisation company for the Queensland University of Technology.

 

qutbluebox Pty Ltd ('bluebox') is our technology transfer and commercialisation company.

bluebox works with our researchers and their discoveries, guiding them through the commercialisation process and taking their innovations to a global market by:

  • identifying and protecting our intellectual property
  • collaborating with our research staff and students in the commercialisation of intellectual property they've created
  • developing and managing commercial relationships between QUT and industry
  • licensing technologies and research outcomes to industry partners
  • forming and managing start-up companies to commercialise technologies developed at QUT
  • negotiating and managing contract research collaborations which involve technology transfer or intellectual property transactions.

Intellectual property

qut bluebox petrie dish

bluebox aims to bring the benefits of QUT's research discoveries to the global market

Our Intellectual Property policy outlines our approach to the commercialisation of our intellectual property and the distribution of any revenue this generates.

Commercialisation achievements

In 2009, we were in the top 25% of Australian universities for:

  • patents granted
  • consulting contracted income.

We have started a number of start-up companies, including:

  • Adalta Pty Ltd
  • Rail Innovation Australia Pty Ltd.
  bluebox sugarcane

Publicly listed companies on the ASX include:

  • Tissue Therapies Ltd: key technologies in novel growth factors and autologous cell therapies for wound healing, tissue repair and cell culture applications.
  • Impedimed Ltd: medical device company focusing on developing and manufacturing non-invasive medical devices using bioimpedance for lymphoedema and body composition (FDA, CE approvals).
  • Agenix Ltd: commercialising monoclonal antibody diagnostics (first University spinoff in 1982 as MabCo; lead candidate is its high-technology blood clot-imaging agent, ThromboView.
  • Evogenix Ltd: offers a fully integrated approach to creating novel antibody products, rapidly converting non-human antibodies to a potent fully humanized product (acquired by Peptech in 2007 for $152 MM, now Arana Therapeutics).
  • PanBio Ltd: markets a wide range of invitro diagnostic tests that are used by hospitals, pathology laboratories and research institutions (acquired by Inverness Medical).
  • Farmacule Bioindustries Pty Ltd: molecular farming company aimed at cost effectively mass producing high-value industrial and therapeutic proteins and biofuels.